Search Results

May 30, 2020, marks the two-year anniversa- ry of the passage of the federal Right to Try law. Like the ex- periences in states that have passed similar legislation, there was consider- able debate over the benefits versus harms that a national Right to Try law would usher in. Proponents argued that existing process- es for patients seeking non-U.S. Food and Drug Administration …

CRISPR, a gene editing tool, has entered the scientific arena and public discourse at an astounding speed. Eric B. Kmiec, PhD, director of the Gene Editing Institute at the Helen F. Graham Cancer Center & Research Institute, discusses the emergence of gene editing, how it can be utilized as a tool in the battle against cancer, and the challenges facing its transition from bench to bedside.